Green Pine Capital Partners

Type

Venture Capital

Status

Active

Location

Shenzhen, China

Total investments

217

Average round size

30M

Portfolio companies

185

Rounds per year

9.04

Lead investments

38

Follow on index

0.15

Exits

11

Stages of investment
SeedEarly Stage Venture
Areas of investment
AutomotiveBiotechnologySoftwareInformation TechnologyArtificial IntelligenceHealth CareManufacturingMedicalHardwareElectronics

Summary

Green Pine Capital Partners appeared to be the VC, which was created in 2000. The leading representative office of defined VC is situated in the Shenzhen. The company was established in Asia in China.

The important activity for fund was in 2018. Speaking about the real fund results, this VC is 18 percentage points more often commits exit comparing to other organizations. The typical startup value when the investment from Green Pine Capital Partners is more than 1 billion dollars. The common things for fund are deals in the range of 50 - 100 millions dollars. The fund is generally included in 2-6 deals every year.

The typical case for the fund is to invest in rounds with 2-3 participants. Despite the Green Pine Capital Partners, startups are often financed by Initial Capital, IDG Capital, FH Capital. The meaningful sponsors for the fund in investment in the same round are Lilly Asia Ventures, Yunqi Partners, Ventech China. In the next rounds fund is usually obtained by Warmsun Holding Group, Taishan Invest AG, Lilly Asia Ventures.

The overall number of key employees were 3.

The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 3 or 4 of the founder, the probability for it to get the investment is little. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight UBTech Robotics, Yaoshibang, MGI Tech. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. We can highlight the next thriving fund investment areas, such as Biotechnology, Pharmaceutical.

Show more

Investor highlights

Industry focus
Deep TechAI/Big DataManufacturingBiotech/Life SciencesEdtech
Geo focus
China

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
217
Lead investments
38
Exits
11
Rounds per year
9.04
Follow on index
0.15
Investments by industry
  • Software (32)
  • Health Care (31)
  • Information Technology (28)
  • Biotechnology (26)
  • Manufacturing (25)
  • Show 159 more
Investments by region
  • China (204)
  • United States (11)
  • Canada (1)
Peak activity year
2016
Number of Unicorns
8
Number of Decacorns
8
Number of Minotaurs
5

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
9
Avg. valuation at time of investment
145M
Group Appearance index
0.71
Avg. company exit year
13
Avg. multiplicator
82.86
Strategy success index
1.00

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Geneplus-Beijing Co. Ltd. 09 Sep 2016 Biotechnology, Health Diagnostics Early Stage Venture 30M
Jiangxing Intelligence 10 Jun 2024 Cloud Computing Early Stage Venture Jiangsu, Xuanwu District, China

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.